Pennsylvania earns a B, ranking 19th of 51 states in overall health. For a state of nearly 13 million people anchored by two of America's largest academic medical systems, that should sting. UPMC operates more than 40 hospitals across western Pennsylvania. Penn Medicine and Jefferson Health define the Philadelphia health corridor. The state pulls in $360 million in NIH funding, 4th in the country, and hosts nearly 30,000 active clinical trials. By those measures, Pennsylvania is a health powerhouse.
So why does one in five Pennsylvania adults still smoke? Why does the drinking rate rank worse than 45 other states? Both numbers sit in the bottom five nationally. Both are driving the cardiovascular disease, liver failure, and lung cancer that Pennsylvania's world-class hospitals spend billions of dollars treating. The state has built extraordinary medicine for the diseases it continues to cause.
The death rate tells a genuine success story: 8,736 deaths per 100,000, well below the national average of 10,368. The uninsured rate beats most states. Child poverty runs below the national figure. These are real wins. But the gap between Chester County, with a median household income above $120,000 and one of the lowest death rates in the state, and Forest County, where residents earn under $50,000 and die at more than three times Chester's rate, tells you what the statewide average conceals. Pennsylvania's B grade is an average of two very different states within one.
Start with the number that doesn't fit. Pennsylvania ranks 19th overall in health. It ranks 46th in adult smoking. Those two numbers shouldn't coexist. At 19.4%, roughly one in five adults smokes, nearly three points above the national rate and worse than 45 states. Rhode Island, ranked first nationally, reports an 11% smoking rate. Pennsylvania's is nearly double. That's not a gap. That's a structural failure.
Smoking predicts. It drives chronic obstructive pulmonary disease, lung cancer, and vascular disease with a lag of years. The patients Pennsylvania's hospitals will treat for those conditions in 2030 are smoking today. The state's healthcare system will absorb that cost whether it's ready or not.
Obesity sits at 37.6%, touching one in three residents, essentially matching the national rate. Physical inactivity runs at 24.5%, roughly one in four adults not moving enough. The two most prescribed drugs in the state are a cholesterol medication and a blood pressure medication: over 7 million claims for Atorvastatin, nearly 5 million for Amlodipine. Pennsylvania is treating the downstream consequences of an upstream problem it hasn't solved.
The drinking rate compounds everything. At 20%, one in five adults drinks excessively, worse than all but five states. Even Mississippi, last in the country in overall health, reports only 13.4% excessive drinking. Pennsylvania's drinking problem drives liver disease, compounds mental health conditions, and feeds emergency visits that quietly erode the state's better numbers. You don't build your way out of that with a new hospital wing.
There's a relative bright spot: the uninsured rate sits at 9.6%, below the national figure of 11.4%. The median household income of $67,683 edges above the national median. For roughly 1.2 million Pennsylvanians without coverage, though, those averages mean nothing. And with 17% of children living in poverty, the foundation for the next generation's chronic disease burden is already laid.
Pennsylvania's screening numbers are a genuine strength. More than 62% of adults visited a dentist in the past year, five points better than the national average. Mammography use among women 50 to 74 reaches 76.8%, more than three points ahead nationally. Colorectal cancer screening comes in at 63.7%, again three points above the national rate. These aren't marginal wins. They're consistent margins across multiple prevention measures, suggesting a population with real access to the healthcare system that actually uses it.
The tooth loss data reinforces the picture: just 15% of adults 65 and older have lost all their teeth, a point better than the national average. That's a lifetime proxy for dental access and preventive care. Pennsylvania's elderly population has used the system more consistently than most.
Then comes sleep. 38.6% of adults report short sleep duration, nearly two points worse than the national average. More than one in three Pennsylvanians is chronically underslept. Poor sleep drives obesity, cardiovascular disease, and depression. It also correlates with shift work, long commutes, and the economic stress of post-industrial communities. The CDC captures it in the data. Pennsylvania doesn't have a policy for it.
What the deviation chart reveals is a state that has institutionalized preventive screening reasonably well but hasn't moved the behavioral needle. Getting the mammogram and going home to smoke doesn't resolve the underlying risk. Pennsylvania's screening rates are among the country's best. Its smoking rate is among the country's worst. Both are true at once.
Pennsylvania's income inequality index of 4.38 reflects a state pulled in two directions. Philadelphia's collar counties and Pittsburgh's professional neighborhoods drive the statewide average upward. The former steel and coal towns, Johnstown, Altoona, McKeesport, sit far below it. The median income looks reasonable from a distance. It conceals the depth of what lies underneath.
About 17% of children live in poverty, below the national figure of 19.4% but still representing hundreds of thousands of kids growing up with food insecurity, housing instability, and constrained access to mental health care. Children who grow up in those conditions carry higher rates of asthma, obesity, and mental illness into adulthood. Pennsylvania's child poverty rate is better than average. It's still a foundation for the next generation's chronic disease burden.
Transportation shapes access across the state's rural interior in ways that don't show up in provider counts or insurance statistics. In Fayette, Cameron, and Forest counties, patients may live an hour or more from a specialist. For someone managing diabetes, heart failure, or cancer, that distance isn't inconvenient. It's the difference between staying in treatment and dropping out of it entirely.
Philadelphia presents the paradox in its sharpest form. The county's death rate of nearly 12,000 per 100,000 puts it among the five worst in the state, despite hosting multiple world-class academic medical centers. The hospitals are there. The outcomes aren't following. Concentrated poverty in North and West Philadelphia generates chronic stress loads that track through cardiovascular disease, infant mortality, and mental illness long before they reach a hospital bed. The city's research output doesn't automatically become community health.
The numbers look strong on paper. Pennsylvania has 222,560 licensed providers, with 76,746 enrolled in Medicare. Of those, 95.5% accept Medicare patients, 2nd in the country. Mental health counselors lead the specialty count at more than 22,500, followed by nurse practitioners at 18,480. The state operates 188 hospitals, 657 nursing homes, 306 dialysis facilities, and 414 home health agencies. The infrastructure looks solid.
Then read the shortage designations. 387 primary care shortage areas cover more than 11.4 million people. That's nearly the entire state population of 13 million. 136 mental health shortage areas leave almost 10 million residents underserved, despite mental health counselors representing the largest single provider specialty in the workforce. How does a state with 22,500 mental health counselors still have 136 shortage areas?
Distribution. Providers cluster where the jobs, salaries, and amenities already are: Philadelphia, Pittsburgh, the collar counties. Rural corridors, post-industrial cities, and isolated northern counties don't pull the workforce regardless of the need. 490 dental shortage areas underscore the point. Pennsylvania outperforms nationally on dental visit rates, but the infrastructure isn't reaching every community equally.
Telehealth hasn't filled the gap. Only about 12,327 Medicare-enrolled providers offer telehealth services, roughly 16% of that workforce. For a state with Pennsylvania's geographic variation and its documented rural access gaps, that penetration rate falls well short of what the shortage problem demands.
Pennsylvania's emergency rooms absorb 611 visits per 1,000 residents annually. Some of those are genuine emergencies. A significant share reflects what happens when 387 primary care shortage areas cover most of the state's population: patients who can't get a timely appointment, or can't afford one, use the ER as the path of least resistance.
Getting into the hospital is one problem. Staying out of it is another. Care continuity gaps run deepest in the lower-income counties where disease burden is highest and follow-up infrastructure is thinnest. The emergency room absorbs what the rest of the system doesn't reach.
One drug accounts for $2.4 billion of Pennsylvania's annual prescription drug bill. Apixaban, a blood thinner for patients with atrial fibrillation, generates that figure on about 3 million claims. That's more than twice the cost of the next most expensive drug on the list. It reflects two realities at once: an aging population and the cardiovascular consequences of decades of smoking and poor metabolic control. The drug works. The patients who need it are, in many cases, the product of risk factors that could have been addressed earlier.
The rest of the drug spending tells the same story in smaller numbers. Atorvastatin leads by claims volume at 7.3 million, treating cholesterol. Lisinopril and Amlodipine together map the scope of hypertension. Metformin at nearly 3 million claims marks the diabetes load. Levothyroxine's 4.7 million claims track thyroid disease at population scale. The state spends $21.9 billion annually across 144.6 million prescription claims, most of it treating conditions strongly linked to smoking, obesity, and inactivity. Gabapentin at 3.3 million claims tracks neuropathic pain management and, in Pennsylvania's opioid context, a drug with growing misuse potential.
Insurance coverage concentrates around a few dominant networks. Aetna leads with nearly 100,000 participating providers. Highmark's multiple entities hold a dominant position in western Pennsylvania, where its long-running conflict with UPMC has produced one of the most contentious insurer-hospital relationships in American healthcare. UnitedHealthcare and its subsidiary UMR together reach nearly 126,000 participating providers. The uninsured rate of 9.6% sits below the national average. For the roughly 1.2 million Pennsylvanians without coverage, network complexity and out-of-pocket costs remain real barriers.
The pharmaceutical industry paid $98.7 million to Pennsylvania doctors and healthcare providers across 623,000 payments from 985 companies. That money reached nearly 45,000 physicians, roughly one in five of the state's Medicare-enrolled provider base.
Speaking and faculty fees accounted for $27 million across around 10,000 payments. Some physicians earn significant income presenting at industry-funded events. Consulting fees added another $25 million. Royalties and licensing generated $14.3 million from just 454 transactions, pointing to high-value partnerships between pharmaceutical companies and academic researchers at Penn, Pitt, Temple, and Drexel. Food and beverage payments, the most numerous category at over 571,000 individual transactions, totaled $16.2 million: the routine office visits and dinner presentations that represent the industry's most diffuse physician contact.
These partnerships aren't inherently improper. Pennsylvania's research universities have legitimate scientific relationships with industry. But the scale of speaking and consulting fees raises real questions about prescribing patterns, particularly for expensive newer drugs where industry promotion shapes adoption curves. Apixaban's $2.4 billion state cost doesn't materialize without aggressive physician outreach. Neither do the speaking fees that support it.
Pennsylvania has 196 actively excluded providers, currently barred from participation in federal healthcare programs. That number places the state worse than 46 others on this measure, a striking gap relative to its 19th-place overall standing. The District of Columbia, ranked 25th overall, has just four excluded providers. Pennsylvania's count is nearly 50 times DC's. Population difference explains some of that. It doesn't explain most of it.
Beyond exclusions, 1,716 providers have opted out of Medicare entirely, 7.7 per 1,000 Medicare-enrolled physicians. Opting out is a legal choice, not misconduct. But it shrinks the accessible Medicare workforce in a state with a large and aging population. In Philadelphia and Pittsburgh, high-earning specialists can sustain cash-pay practices. In rural counties, patients who can't cover out-of-pocket rates and can't easily travel don't have that option. One provider's business decision is another patient's lost access.
For a state that ranks 2nd nationally on Medicare acceptance and 4th on NIH research funding, 196 excluded providers is a real inconsistency. It suggests oversight gaps or fraud patterns that don't match Pennsylvania's self-image as a well-managed healthcare state. The number deserves more scrutiny than it gets.
Pennsylvania is a research powerhouse, and the numbers aren't close. $359.8 million in NIH funding across 749 grants places the state 4th nationally. The per-capita figure of $28 per person compares to under $1 in Idaho and Wyoming. The clinical trial count of 29,950 active trials ranks 5th nationally, a figure that reflects the reach of Penn Medicine, UPMC, Jefferson, Temple, Drexel, and the Wistar Institute operating across one of the densest biomedical research corridors in the world.
The University of Pennsylvania's medical school produced foundational work on mRNA vaccine technology. UPMC in Pittsburgh runs one of the largest organ transplant programs in the country. Children's Hospital of Philadelphia ranks consistently among the top pediatric institutions nationally. This didn't happen by accident. It's the product of sustained public and private investment over decades, and it shows in both the funding totals and the trial count.
And yet one in five Pennsylvania adults still smokes. The state funds some of the most sophisticated medical science anywhere and can't bring that number below 20%. Research advances treatments. It doesn't automatically change behavior. In Pennsylvania, behavior is where the grade keeps slipping, and the research enterprise hasn't been turned toward fixing it.
The gap between Pennsylvania's healthiest and sickest counties runs at a factor of 3.6. Centre County, home to Penn State University, reports a death rate of 4,450 per 100,000. Forest County, sparsely populated and rural in the state's northwest, reaches 15,982. Those two numbers exist in the same state, funded by the same Medicaid program, covered by the same insurance exchanges. The distance between them isn't a rounding error. It's a policy failure measured in years of life.
Chester County in the Philadelphia suburbs earns a median household income of $120,925 and a death rate near 4,900. Fayette County in the southwestern corner, near the West Virginia border, earns $54,030 and sees a death rate of 12,648. Montgomery County, also in the Philadelphia suburbs, earns nearly $107,000. Lawrence County, former steel country to the west, earns $61,686 and reports a death rate above 11,000.
The pattern holds across Pennsylvania's 67 counties. Philadelphia's collar counties and Pittsburgh's professional neighborhoods cluster near the top. The rural interior, the old coal and steel corridors of the southwest, and isolated northern counties like Cameron County cluster near the bottom. Philadelphia County itself is the complicated case: a death rate of nearly 12,000 despite hosting multiple world-class medical systems, driven by concentrated poverty in North and West Philadelphia where the hospitals' reach stops short of the populations that need them most. The city contains both some of the best and some of the worst health outcomes in the state, often in neighborhoods a few miles apart.
Pennsylvania's B grade is real. The death rate below the national average, the broad Medicare network, the strong screening rates, the research infrastructure: these reflect decades of investment that have paid off in measurable ways. The grade isn't inflated.
But it's an average, and averages hide what's underneath. The smoking and drinking rates in the bottom five nationally aren't anomalies. They're the behavioral signature of post-industrial communities where economic loss became chronic stress, chronic stress became addiction, and addiction became the cardiovascular and liver disease that Penn Medicine and UPMC are extraordinarily well-equipped to treat. The institutions are solving the problem at the end of the pipeline. Nobody is solving it at the beginning.
Pennsylvania ranks worse than 45 states on smoking and worse than 45 on excessive drinking. It ranks 2nd on Medicare acceptance and 4th on NIH funding. The state's best and worst ranks don't describe the same Pennsylvania. They describe two states, divided by geography and income, that share a Medicaid program and a report card grade but not much else. Fayette County and Forest County don't need more clinical trials. They need the results of the last fifty years of them, applied at the community level, in the places where a B-grade state is still failing the people who live inside it.